Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data

Journal of Medicinal Chemistry

Volumn 45, Issue 13, 2002, Pages 2867-2876

  Lombardo, Franco ^a   Obach, R Scott ^a   Shalaeva, Marina Y ^a   Gao, Feng ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ALLOPURINOL; ALPRAZOLAM; ALPRENOLOL; AMIODARONE; ATROPINE; AZELASTINE; BROMAZEPAM; CAFFEINE; CHLORAMPHENICOL; CHLORPHENIRAMINE; CHLORPROMAZINE; CIMETIDINE; CLONIDINE; CLOZAPINE; COCAINE; COLCHICINE; DESIPRAMINE; DEXAMETHASONE; DIAZEPAM; DILTIAZEM; DIPHENHYDRAMINE; ERGOTAMINE; ESTRADIOL; FELODIPINE; FENTANYL DERIVATIVE; NIZATIDINE; PHENAZONE; PLASMA PROTEIN; UNINDEXED DRUG;

ACCURACY; ARTICLE; COMPUTER ANALYSIS; DATA ANALYSIS; DRUG DISTRIBUTION; HUMAN; IONIZATION; LABORATORY AUTOMATION; PH; PHYSICAL CHEMISTRY; PKA; PLASMA PROTEIN BINDING; PREDICTION; REFERENCE VALUE; REGRESSION ANALYSIS;

BLOOD PROTEINS; CHEMISTRY, PHYSICAL; HALF-LIFE; HUMANS; HYDROGEN-ION CONCENTRATION; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PROTEIN BINDING;

EID: 0037142338     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0200409     Document Type: Article

References (99)

1. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data
2. Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices
3. Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations
4. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data
5. oct: A tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds
6. Effect of altered plasma protein binding on apparent volume of distribution
7. Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics
8. Quantitative structure pharmacokinetic relationships for systemic drug distribution kinetics not confined to a congeneric series
9. Prediction of adipose tissue: Plasma partition coefficients for structurally unrelated drugs
10. Theil plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery
11. Factors affecting the storage of drugs and other xenobiotics in adipose tissue
12. Pharmacokinetics of β-adrenoceptors blockers in obese and normal volunteers
13. The influence of lipophilicity on the pharmacokinetic behavior of drugs: Concepts and examples
14. Submitochondrial distribution of basic drugs in the isolated perfused lung
15. Prediction of the volumes of distribution of basic drugs in humans based on data from animals
16. a screening of pharmaceuticals by pressure-assisted capillary electrophoresis
17. Multiwavelength spectrophotometric determination of acid dissociation constants of ionizable drugs
18. High throughput physicochemical profiling for drug discovery
19. Physiological parameters in laboratory animals and humans
20. Development of a high throughput equilibrium dialysis methodol
21. Acebutolol, a review of its pharmacology, pharmacokinetics, clinical uses, and adverse effects
22. Clinical pharmacokinetics of paracetamol
23. Metabolic studies of allopurinol, an inhibitor of xanthine oxidase
24. Clinical pharmacokinetics of alprazolam
25. Quantitative relationships between structure and pharmacokinetics of β-adrenoceptor blocking agents in man
26. Amiodarone: An overview of its pharmacological properties and review of its therapeutic use in cardiac arrhythmias
27. Comparison of plasma levels of antipyrine, tolbutamide, and warfarin after oral and intravenous administration
28. Intramuscular atropine in healthy volunteers: A pharmacokinetic and pharmacodynamic study
29. 1 Receptor Antagonists
30. Zur pkarmakokinetik von bromazepam beim menschen
31. Clinical pharmacokinetics of nonopiate abused drugs
32. Clinical pharmacokinetics of chloramphenicol and chloramphenicol succinate
33. Clinical pharmacokinetics of chlorpheniramine
34. Pharmacokinetics of chlorpromazine after single and chronic dosage
35. Age, disease, and cimetidine disposition in healthy subjects and chronically ill patients
36. Clinical pharmacokinetics of clonidine
37. Pharmacokinetics and pharmacodynamics of clozapine
38. Cocaine disposition in humans after intravenous injection, nasal insufflation (snorting), or smoking
39. Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects
40. Tolerance and disposition of tetrahydrocannabinol in man
41. 9-tetrahydrocannabinol
42. Clinical pharmacokinetics of imipranine and desipramine
43. Disposition of synthetic glucocorticoids. I. Pharmacokinetics of dexamethasone in healthy adults
44. Diazepam dispositional determinants
45. Clinical pharmacokinetics of verapamil, nifedipine, and diltiazem
46. Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration
47. Linear pharmacokinetics of intravenous ergotamine tartrate
48. Pharmacokinetics of estradiol, free and total estrone, in young women following single intravenous and oral administration of 17β-estradiol
49. Felodipine clinical pharmacokinetics
50. Clinical pharmacokinetics and pharmacodynamics of opioid analgesics in infants and children
51. Variable disposition and electrocardiographic effects of flecainide during repeated dosing in humans: Contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone
52. Clinical pharmacokinetics of fluconazole
53. Pharmacokinetics of haloperidol
54. A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection
55. The pharmacokinetics of lignocaine and β-adrenoreceptor antagonists in patients with acute myocardial infarction
56. Clinical pharmacokinetics of oxazepan and lorazepam
57. The pharmacokinetics and biotransformation of the new benzodiazepine lormetazepam in humans. I. Absorption, distribution, elimination and metabolism of lormetazepam-5-14C
58. Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part 1)
59. Plasma concentrations and beta blocking effects in normal volunteers after intravenous doses of metoprolol and propranolol
60. Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives
61. Mexiletine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrythmias
62. Clinical pharmacokinetics of morphine
63. Clinical pharmacokinetics of nefazodone
64. Nicotine and cotinine elimination pharmacokinetics in smokers and nonsmokers
65. Intraindividual variability in nifedipine pharmacokinetics and effects in healthy subjects
66. Interphenotype differences in disposition and effect on gastrin levels of omeprazole-suitability of omeprazole as a probe for CYP2C19
67. Clinical pharmacokinetics of paclitaxel
68. Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients
69. Clinical pharmacokinetics of prednisone and prednisolone
70. Prednisone for chronic active liver disease: Pharmacokinetics, including conversion to prednisolone
71. Pharmacokinetics of procainamide intravenously and orally as conventional and slow release tablets
72. Propafenone, a reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias
73. Age and propranolol stereoselective disposition in humans
74. The pharmacological basis for the rational use of atabrine in the treatment of malaria
75. Pharmacokinetics of quinidine in humans after intravenous, intramuscular, and oral administration
76. 2 receptor antagonists in patients with renal insufficiency
77. Risperidone
78. Sumatriptan clinical pharmacokinetics
79. Interspecies scaling of tebufelone pharmacokinetic data and application in preclinical toxicology
80. Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate
81. Pharmacokinetics and pharmacodynamics of tolterodine in man. A new drug for the treatment of urinary bladder overactivity
82. Single dose pharmacokinetics of trazodone in healthy subjects
83. Disposition of drugs in cystic fibrosis. I. Sulfamethoxazole and trimethoprim
84. Relationships between octanol-water partition data, chromatographic indices and their dependence on pH in a set of beta-adrenoceptor blocking agents
85. Lipophilicity and brain disposition of clonidine and structurally related imidazolidines
86. New approach of the extrapolation procedure in the determination of acid-base constants of poorly soluble pharmaceuticals
87. Ergotamine Tartrate
88. Plasma protein binding and distribution of fentanyl, sulfentanil, alfentanil and lofentanil in blood
89. Flecainide
90. Procainamide hydrochloride
91. Apparent ionization exponents of homologues of quinacrine; electrostatic effects
92. Influence of stereochemical factors on the partition coefficient of diastereomers in a biphasic octan-1-ol/water system
93. Influence of the physicochemistry on the brain penetration of the triptans in rat